Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Gross Margin (2016 - 2025)

Immucell's Gross Margin history spans 16 years, with the latest figure at 38.16% for Q4 2025.

  • For Q4 2025, Gross Margin rose 163.0% year-over-year to 38.16%; the TTM value through Dec 2025 reached 41.4%, up 1196.0%, while the annual FY2025 figure was 41.4%, 1143.0% up from the prior year.
  • Gross Margin reached 38.16% in Q4 2025 per ICCC's latest filing, down from 42.92% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 51.72% in Q1 2022 to a low of 8.73% in Q1 2023.
  • Average Gross Margin over 5 years is 35.88%, with a median of 38.49% recorded in 2022.
  • Peak YoY movement for Gross Margin: crashed -4300bps in 2023, then surged 2305bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 47.04% in 2021, then crashed by -46bps to 25.37% in 2022, then dropped by -7bps to 23.48% in 2023, then soared by 56bps to 36.53% in 2024, then rose by 4bps to 38.16% in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Gross Margin are 38.16% (Q4 2025), 42.92% (Q3 2025), and 43.72% (Q2 2025).